CAR T-cell therapy—paving the way for sensitized kidney transplant patients

Organ transplant demands, especially among patients with kidney failure, far surpass the current availability of organs. This challenging situation is further compounded by the presence of pretransplant high levels of anti–human leukocyte antigen (HLA) antibodies, clinically known as sensitization,1 making the matching process a highly complex one. Consequently, the waiting time on a transplant waitlist can be substantially lengthy, resulting in dire consequences where patients may tragically succumb to organ failure before receiving a life-saving organ transplant.